Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.

The new recommendations drew mixed reactions from experts, who criticized the emphasis on meat and dairy while praising ...

If the treatment wins FDA approval, its success will depend on pricing. Vera's rival, Otsuka Pharmaceutical, which earned an ...

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53466. For those unable to listen to the live webcast, an archived version will also be ...

Shortly after securing a partnership with Sanofi, InduPro is linking up with Eli Lilly in efforts to discover new cancer ...

Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader therapies, today announced its attendance at ...

Shares in Monte Rosa Therapeutics (NASDAQ:GLUE) climbed around 13% after the company released encouraging interim results ...

Corsera, which emerged in September 2025, aims to extend healthspan by reducing the risk of atherosclerotic cardiovascular ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Building a technology moat is hard for any company, but especially for alternative protein. Co-manufacturing, ingredient ...

According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...